AZD8835 is primarily used in the field of oncology as a potent and selective inhibitor of PI3Kα and PI3Kδ isoforms. Its application is focused on targeting cancer cells by disrupting the PI3K signaling pathway, which is often dysregulated in various cancers. This compound is particularly investigated for its potential in treating hematologic malignancies and solid tumors. By inhibiting these specific isoforms, AZD8835 aims to reduce tumor growth and improve patient outcomes. It is often studied in combination with other therapies to enhance its efficacy and overcome resistance mechanisms in cancer treatment. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in different cancer types.